checkAd

     443  0 Kommentare Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment - Seite 4

    3 Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate



    Lesen Sie auch

    Attachment



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    2 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment - Seite 4 Vaccine production initiated to optimize timeline for potential deliveries Phase 1/2 clinical study now fully enrolled; initial data read out expected in April 2021 Saint-Herblain (France), January 28, 2021 – Valneva SE, a specialty vaccine company …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer